Certara Products - Phoenix Archives | Page 3 of 4

Case Study

バイオテクノロジー新興企業がPhoenix Hostedに切り替えて柔軟性と効率を高めた方法

Discover how a biotech startup enhanced flexibility and efficiency by adopting Phoenix Hosted, streamlining workflows…

Danielle Pillsbury2023年9月8日

Case Study

薬物動態モデリングおよび科学的コミュニケーションの専門性を活用することで、サルコイドーシス治療薬開発プログラムの前進に貢献

Certara's support, from dose optimization to medical writing, helps pharmaceutical companies advance their research, make…

Danielle Pillsbury2023年6月1日

Blog

Application of PK/PD Modeling and Simulation in Drug Discovery and Development in China

By Yuancheng Chen, Research Associate of Phase 1 Unit, Huashan Hospital, Fudan University, and visiting…

Certara2020年8月7日

Blog

Reference-scaled Average Bioequivalence

The standard approach for approval of generic drugs is to run a bioequivalence study to…

Certara2016年5月12日

ブログ

Conventional & Mechanistic IVIVC: Complementary or Clashing Methods?

An IVIVC (in vitro-in vivo correlation) is a mathematical relationship that predicts key pharmacokinetic parameters…

Certara2016年2月9日

Blog

Common Misconceptions About Computer System Validation

Drug development professionals frequently use computer systems to help them understand the pharmacokinetics (PK) and…

Certara2015年1月28日

Blog

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

As a scientist at Certara and proud Dad to my three kids, pediatric drug development…

Certara2015年1月15日

Blog Knowledge Base

Understanding Steady State Pharmacokinetics

“Steady state” is an important term in pharmacokinetics, but it can often seem a bit…

Certara2013年11月25日

Blog Knowledge Base

Calculating Urine PK Parameters

Pharmacokinetic analysis normally focuses on systemic exposure to a drug; however, much can be learned…

Certara2012年12月6日

Blog Knowledge Base

The Difference Between Vd and Vss

There are many terms used to represent volume of distribution, but two common ones are…

Certara2011年3月31日

Certara Products – Phoenix

バイオテクノロジー新興企業がPhoenix Hostedに切り替えて柔軟性と効率を高めた方法

薬物動態モデリングおよび科学的コミュニケーションの専門性を活用することで、サルコイドーシス治療薬開発プログラムの前進に貢献

Application of PK/PD Modeling and Simulation in Drug Discovery and Development in China

Reference-scaled Average Bioequivalence

Conventional & Mechanistic IVIVC: Complementary or Clashing Methods?

Common Misconceptions About Computer System Validation

Using Modeling and Simulation to Quantify the PK of an Anti-HIV Drug for Babies

Understanding Steady State Pharmacokinetics

Calculating Urine PK Parameters

The Difference Between Vd and Vss

メルマガ登録

クイックアクセス

ソリューション

お問合せ